Palatal myoclonus following Behçet's disease ameliorated by ceruletide, a potent analogue of CCK octapeptide

J Neurol Sci. 1991 Sep;105(1):12-3. doi: 10.1016/0022-510x(91)90111-j.

Abstract

Systemic administration of ceruletide, a potent analogue of CCK octapeptide (0.8 microgram/kg, i.m.) markedly improved palatal myoclonus. CCK analogues may be useful agents for the treatment of palatal myoclonus. This report suggests that dopaminergic system may also contribute to the underlying biochemical mechanism of palatal myoclonus.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Behcet Syndrome / drug therapy*
  • Ceruletide / adverse effects*
  • Ceruletide / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Myoclonus / chemically induced*
  • Myoclonus / physiopathology
  • Palatal Muscles / drug effects*
  • Palatal Muscles / physiopathology

Substances

  • Ceruletide